Istari Oncology, Inc.

Quick facts

Phase 2 pipeline

• Anti-PD-1 Checkpoint Inhibitor · Oncology
  Inhibits PD-1 receptor
• Lerapolturev · Other

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Istari Oncology, Inc. portfolio CI brief
• Istari Oncology, Inc. pipeline updates RSS

Related

• Sector hub: All tracked pharma companies